MS and Demyelinating Disorders

Experimental small molecule CN045 promoted oligodendrocyte maturation and modest remyelination in preclinical models of multiple sclerosis, supporting further development of the compound as a potential remyelination therapy.

The FDA has cleared Quantum BioPharma's investigational new drug application for Lucid-MS, allowing the company to begin a phase 2 trial of the first-in-class demyelination-targeting compound in progressive multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 7, 2026.

Six FDA PDUFA decisions this fall could reshape care in Alzheimer disease, DMD, Sanfilippo syndrome, Alexander disease, and SMA, here's what clinicians need to know about the data behind each.

A recently published study showed that 4 weeks of high-dose oral N-acetyl cysteine significantly reduced serum GFAP levels in adults with progressive multiple sclerosis compared with placebo.

Real-world data from a London MS pregnancy clinic showed persistent B-cell depletion and favorable postpartum disease outcomes in women who discontinued ofatumumab upon confirmed pregnancy.

Here's some of what is coming soon to NeurologyLive® this week.

John Corboy, MD, professor of neurology at the University of Colorado, discussed recent findings focused on disease-modifying therapy discontinuation in older, stable patients with multiple sclerosis.

Actress Jamie Lynn Sigler discussed how patient education, treatment adherence, and self-advocacy have shaped her approach to living with multiple sclerosis at the 2026 CMSC Annual Meeting.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with neuro-oncologist Na Tosha Gatson, MD, PhD, FAAN. [LISTEN TIME: 20 minutes]

Carrie Hersh, DO, MSc, FAAN, president of the Consortium of Multiple Sclerosis Centers, discussed key sessions presented on disability progression, emerging biomarkers, and the shift toward comprehensive, patient-centered MS care.

Ahmed Obeidat, MD, PhD, associate professor of neurology at the Medical College of Wisconsin, talked about the need to rethink multiple sclerosis clinical trial design by recognizing immune cells’ potential neuroprotective roles.

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC, director of the multiple sclerosis research unit at Ottawa Hospital, outlined how research-integrated multiple sclerosis care can refine treatment strategies in clinical practice.

At CMSC 2026, the assistant professor of neurology at NYU Grossman School of Medicine talked about how optical coherence tomography contributes to the updated 2024 McDonald criteria for multiple sclerosis. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Ahead of World Brain Day, NeurologyLive explores 5 emerging strategies for preventing neurologic disease, from modifiable dementia risk factors to GLP-1 drugs, sleep science, the gut brain axis, and wearable technology.

Here's some of what is coming soon to NeurologyLive® this week.

Mitzi Joi Williams, MD, is joined by Jacquelyn McEwen, MD, and Jacqueline Rosenthal, MD, to discuss the latest updates to MS diagnostic criteria and their impact on diagnosing MS and NMOSD.

A cross-sectional survey of 4181 NARCOMS Registry participants found that only 7.4% had ever used semaglutide or tirzepatide, despite 40% meeting FDA-approved indications for the drugs.

Here's some of what is coming soon to NeurologyLive® this week.

An Oxford study found that current smokers with MOGAD had a 2.2-times higher annualized relapse rate than never smokers, whereas past smokers showed no elevated risk, supporting smoking cessation as a modifiable management target.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 10, 2026.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 20 minutes]

The first randomized, double-blind trial directly comparing the 2 anti-CD20 agents showed rituximab met the prespecified noninferiority criterion on MRI suppression, with a similar serious adverse event profile and a substantially lower cost.